Insider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Sells 9,051 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Michael R. Megna sold 9,051 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the transaction, the chief accounting officer now directly owns 26,528 shares of the company’s stock, valued at $595,553.60. This represents a 25.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Kiniksa Pharmaceuticals Trading Up 2.0 %

KNSA stock opened at $22.61 on Friday. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $16.56 and a 1-year high of $28.15. The firm has a market cap of $1.64 billion, a P/E ratio of -161.49 and a beta of 0.48. The business’s 50 day moving average is $19.95 and its 200-day moving average is $22.22.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The company had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company’s revenue for the quarter was up 46.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.35 earnings per share. Sell-side analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on KNSA shares. Citigroup started coverage on Kiniksa Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $40.00 price objective for the company. Wedbush restated an “outperform” rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $37.17.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Braidwell LP grew its position in Kiniksa Pharmaceuticals by 19.3% during the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company’s stock worth $68,289,000 after acquiring an additional 557,934 shares during the last quarter. Nuveen Asset Management LLC lifted its holdings in Kiniksa Pharmaceuticals by 7.3% during the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company’s stock worth $15,737,000 after buying an additional 54,361 shares in the last quarter. Millennium Management LLC lifted its holdings in Kiniksa Pharmaceuticals by 50.9% during the 4th quarter. Millennium Management LLC now owns 779,672 shares of the company’s stock worth $15,422,000 after buying an additional 263,146 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Kiniksa Pharmaceuticals by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company’s stock valued at $15,262,000 after purchasing an additional 29,300 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its stake in shares of Kiniksa Pharmaceuticals by 1.4% in the 4th quarter. Parkman Healthcare Partners LLC now owns 765,453 shares of the company’s stock valued at $15,141,000 after purchasing an additional 10,209 shares during the period. 53.95% of the stock is currently owned by institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.